eligibility_summary
Adults (≥18) with HPV-associated carcinoma, ECOG 0–1, and at least one RECIST 1.1 measurable lesion are eligible. Excludes patients with active or uncontrolled infections or major cardiovascular/respiratory illness, active autoimmune disease, active hepatitis B or C, or other severe conditions that could limit participation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT06544720 tests SCG142, an autologous TCR‑T cell therapy (biological, cellular immunotherapy) for advanced HPV‑associated carcinomas. Intervention: patient T cells are genetically engineered ex vivo to express a tumor‑specific T‑cell receptor that recognizes HPV-derived antigens presented by HLA on cancer cells, then reinfused as monotherapy. Mechanism of action: TCR–MHC engagement activates cytotoxic T lymphocytes, triggering perforin/granzyme-mediated lysis and cytokine-driven anti-tumor responses. Targets: HPV antigen–expressing epithelial tumor cells. Key pathways: antigen presentation via MHC class I on tumor cells and TCR signaling/effector functions in T cells. Phase: 1, single-arm dose escalation/expansion.